{"filing":{"accession_number":"0001178913-26-004645","cik":"0002022416","ticker":"SLXNW","company_name":"Silexion Therapeutics Corp","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-28","primary_document":"zk2636167.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004645/zk2636167.htm"},"events":[{"id":35668,"run_id":32863,"accession_number":"0001178913-26-004645","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.88,"summary":"Silexion entered into an inducement letter agreement on September 28, 2026, whereby warrant holders exercised existing Series E warrants at a reduced exercise price ($0.2603 vs. $0.65) in exchange for new Series F and G warrants to purchase 6,433,856 additional ordinary shares. The transaction, structured as a private placement under Section 4(a)(2), generates approximately $0.84 million in gross proceeds while creating substantial new dilution through the issuance of 6.4+ million warrant shares.","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39812,"accession_number":"0001178913-26-004645","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Silexion entered into an inducement letter agreement on September 28, 2026, whereby warrant holders exercised existing Series E warrants at a reduced exercise price ($0.2603 vs. $0.65) in exchange for new Series F and G warrants to purchase 6,433,856 additional ordinary shares. This is a dilutive equity issuance structured as a private placement under Section 4(a)(2), with the Company issuing new warrant securities to existing holders. The transaction generates only ~$0.84 million in gross proceeds while creating substantial new dilution through the issuance of 6.4+ million warrant shares, characteristic of a dilutive capital raise at a distressed valuation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T14:32:44.336817+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39813,"accession_number":"0001178913-26-004645","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered sales of equity securities, with the filing incorporating by reference details from Item 1.01 regarding an offering expected to close on or about September 29, 2026. This is a classic dilutive issuance disclosure—an unregistered equity offering that would materially affect existing shareholders through dilution and is a strong signal of capital-raising activity at a small-cap biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T14:32:44.336817+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39814,"accession_number":"0001178913-26-004645","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a reduction in the exercise price of outstanding Series E Warrants (3,846,161 shares) in connection with a closing offering. This warrant repricing materially increases the dilutive potential to existing shareholders by lowering the strike price to $0.2603 per share, making the warrants more likely to be exercised and effectively diluting equity value. While the Item 8.01 classification suggests \"Other Events,\" the substance is a dilutive capital action tied to an offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T14:32:44.336817+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39812,"accession_number":"0001178913-26-004645","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Silexion entered into an inducement letter agreement on September 28, 2026, whereby warrant holders exercised existing Series E warrants at a reduced exercise price ($0.2603 vs. $0.65) in exchange for new Series F and G warrants to purchase 6,433,856 additional ordinary shares. This is a dilutive equity issuance structured as a private placement under Section 4(a)(2), with the Company issuing new warrant securities to existing holders. The transaction generates only ~$0.84 million in gross proceeds while creating substantial new dilution through the issuance of 6.4+ million warrant shares, characteristic of a dilutive capital raise at a distressed valuation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T14:32:44.336817+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-09-29"},{"id":39813,"accession_number":"0001178913-26-004645","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered sales of equity securities, with the filing incorporating by reference details from Item 1.01 regarding an offering expected to close on or about September 29, 2026. This is a classic dilutive issuance disclosure—an unregistered equity offering that would materially affect existing shareholders through dilution and is a strong signal of capital-raising activity at a small-cap biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T14:32:44.336817+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-09-29"},{"id":39814,"accession_number":"0001178913-26-004645","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a reduction in the exercise price of outstanding Series E Warrants (3,846,161 shares) in connection with a closing offering. This warrant repricing materially increases the dilutive potential to existing shareholders by lowering the strike price to $0.2603 per share, making the warrants more likely to be exercised and effectively diluting equity value. While the Item 8.01 classification suggests \"Other Events,\" the substance is a dilutive capital action tied to an offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T14:32:44.336817+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-09-29"}]}